Trials / Completed
CompletedNCT00883233
Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in Acne Vulgaris
Efficacy and Safety Comparison of Four Different Regimens of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 12 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the tolerability of 3 treatment regimens containing Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel with that of Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 weeks in the treatment of acne vulgaris. The efficacy of the four treatment regimens will also be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adapalene BPO Gel standard daily overnight application | Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week |
| DRUG | Adapalene-BPO 3-hour daily application before bedtime | Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks |
| DRUG | Adapalene-BPO Gel every other day application | Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks |
| DRUG | Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion | Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-04-17
- Last updated
- 2021-02-18
- Results posted
- 2010-12-08
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00883233. Inclusion in this directory is not an endorsement.